Pharming Group’s Strong Q3 and CEO Transition
Company Announcements

Pharming Group’s Strong Q3 and CEO Transition

Pharming Group (PHGUF) has released an update.

Pharming Group has reported a strong third quarter in 2024, with total revenues rising by 12% to $74.8 million, driven by growth in its RUCONEST® and Joenja® products. The company’s operating profit also saw a significant increase, and they remain on track to achieve their annual revenue guidance. CEO Sijmen de Vries announced he will step down after a successful 16-year tenure, with a search for his successor underway.

For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyPharming price target lowered to EUR 1.60 from EUR 1.65 at RBC Capital
TheFlyPharming price target lowered to $30 from $31 at Oppenheimer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App